kauft man auch jetzt
Anzeige
Meldung des Tages: Diese Biotech-Aktie steht wieder am 2025er Aufwärtstrend – und der Markt könnte erneut falsch liegen
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 15 16 17 19 20 21
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 15 16 17 19 20 21
Generex Biotech Corp
Beiträge:
515
Zugriffe: 161.392 / Heute: 15
Zugriffe: 161.392 / Heute: 15
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi IBEX 35 Doble Apalancado Diario (2x) UCITS ETF Acc
Perf. 12M: +122,96%
Amundi MSCI Greece UCITS ETF Dist
Perf. 12M: +58,75%
Amundi IBEX 35 UCITS ETF Acc
Perf. 12M: +55,15%
Amundi IBEX 35 UCITS ETF Dist
Perf. 12M: +53,92%
kommen auch die investoren von dendreon hier.
so stark ist dort der kurs gefallen
so stark ist dort der kurs gefallen
german.ruvr.ru/news/2014_10_13/...t-fertig-Vizepremierin-7219/
das glaube ich nicht, sonst wäre auch in unseren nachrichten etwas gekommen.
nach google suche: gsk und eine kanadische firma entwickeln derzeit impfstoffe, die
vielleicht auch wirken
nach google suche: gsk und eine kanadische firma entwickeln derzeit impfstoffe, die
vielleicht auch wirken
dnd hat chapter 11 beantragt.
-75% heute und es geht noch weiter so.
-75% heute und es geht noch weiter so.
Generex Announces Presentation at the Society for Immunotherapy of Cancer Demonstrating that Induction of Antibody Response in Patients Receiving the AE37 Breast Cancer Vaccine Correlates with Reduced Relapse
aber was ist hier los?
www.sec.gov/Archives/edgar/data/1059784/...14-000200-index.htm
gibt es geldprobleme?
oder liegt es daran, dass bayer ein krebsmittel entwickelt?
www.sec.gov/Archives/edgar/data/1059784/...14-000200-index.htm
gibt es geldprobleme?
oder liegt es daran, dass bayer ein krebsmittel entwickelt?
bekommen leider immer zum schluss mit, was los war und was jetzt los ist.
Dann hoffen wir mal dass die Phase III erfolgreich wird und AE37 ein Hit :)
Here Comes Reversal: Generex Biotechnology Corporation (OTCMKTS:GNBT)
0
By Dave Young on January 17, 2015 BioPharma, Micro Cap Inside
Generex Biotechnology Corporation (OTCMKTS:GNBT) is making a huge move up on record breaking volume after the stock hit a recent low of $0.0105. The move comes as a big welcome for GNBT shareholders who have endured steady declines since GNBT was over $0.25 a share back in 2012.
Now that GNBT has reversed off a penny on huge volume and the Company announced an acquisition which puts them in the pot sector speculators are giving this one another look. GNBT is a stock with a history of explosive moves running from well under a dime to over $0.30 in 2012.
Generex Biotechnology Corporation (OTCMKTS:GNBT) is a Company with an exciting story behind it; The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.
The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device.
GNBT also has a wholly owned subsidiary Antigen Express, Inc. focused on immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.
Antigen Express has previously published its work on the development of a vaccine for potentially pandemic viruses such as the H5N1 (avian flu) and H1N1 (swine flu) influenza strains. The advantage of the technology is that it entails entirely synthetic production methods, which are rapid, cost effective, and flexible. The vaccine is produced using a small fragment derived from a target protein modified to ensure activation of CD4+ T helper cells. This cell type is critical in the generation of an effective immune response to a novel agent.
To Find out the inside Scoop on GNBT Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
GNBT entered the red hot pot sector when they announced that it has acquired a substantial minority equity stake in CannScience, a leading cannabinoid drug development firm. This partnership positions MedCannAccess to be a leader in the development of pharmaceutical cannabinoid products.
CannScience is an R&D biopharmaceutical company established in Toronto, Canada to conduct research and product development for extracts and formulations related to medical cannabis and its derivatives. CannScience is developing proprietary technologies and owns know-how related to the chemistry and pharmacology of cannabinoids and potentially how they integrate with various medical devices and drug delivery technologies. CannScience intends to develop commercial ready products and obtain regulatory approval for RapidMist™ in the Canadian and international jurisdictions. The company’s founders have a wealth of experience in the life sciences industry and access to laboratories at some of the top research institutions in Canada.
CannScience CEO Har Grover said ”CannScience is working to develop its product pipeline which will include proprietary drug, device, and delivery technologies, On November 18, 2014, CannScience entered into a non-binding Letter of Intent with Generex to license Generex’s proprietary RapidMist™ drug delivery technologies to CannScience for the buccal delivery of cannabis derived products into the bloodstream.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $15 million market valuation GNBT is cheaper now than it has ever been and used to trade at a valuation close to $100 million at its highs in 2012. The Company does have $2.2 million in the treasury and carries $1.9 million in patents on the books however they are carrying significant debt with $7.4 million in accounts payable.
GNBT has been losing ground for years and the current reversal off the $0.0105 represents a significant shift for the stock. Whether GNBT can maintain this turnaround remains to be seen but the volume and steady accumulation in recent days are very positive indicators indeed. At just over a penny GNBT deserves to be on speculators radars.
Disclosure: we hold no position in GNBT either long or short and we have not been compensated for this article.
www.microcapdaily.com/...nology-corporation-otcmktsgnbt/18310/
0
By Dave Young on January 17, 2015 BioPharma, Micro Cap Inside
Generex Biotechnology Corporation (OTCMKTS:GNBT) is making a huge move up on record breaking volume after the stock hit a recent low of $0.0105. The move comes as a big welcome for GNBT shareholders who have endured steady declines since GNBT was over $0.25 a share back in 2012.
Now that GNBT has reversed off a penny on huge volume and the Company announced an acquisition which puts them in the pot sector speculators are giving this one another look. GNBT is a stock with a history of explosive moves running from well under a dime to over $0.30 in 2012.
Generex Biotechnology Corporation (OTCMKTS:GNBT) is a Company with an exciting story behind it; The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity.
The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist™ device.
GNBT also has a wholly owned subsidiary Antigen Express, Inc. focused on immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.
Antigen Express has previously published its work on the development of a vaccine for potentially pandemic viruses such as the H5N1 (avian flu) and H1N1 (swine flu) influenza strains. The advantage of the technology is that it entails entirely synthetic production methods, which are rapid, cost effective, and flexible. The vaccine is produced using a small fragment derived from a target protein modified to ensure activation of CD4+ T helper cells. This cell type is critical in the generation of an effective immune response to a novel agent.
To Find out the inside Scoop on GNBT Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
GNBT entered the red hot pot sector when they announced that it has acquired a substantial minority equity stake in CannScience, a leading cannabinoid drug development firm. This partnership positions MedCannAccess to be a leader in the development of pharmaceutical cannabinoid products.
CannScience is an R&D biopharmaceutical company established in Toronto, Canada to conduct research and product development for extracts and formulations related to medical cannabis and its derivatives. CannScience is developing proprietary technologies and owns know-how related to the chemistry and pharmacology of cannabinoids and potentially how they integrate with various medical devices and drug delivery technologies. CannScience intends to develop commercial ready products and obtain regulatory approval for RapidMist™ in the Canadian and international jurisdictions. The company’s founders have a wealth of experience in the life sciences industry and access to laboratories at some of the top research institutions in Canada.
CannScience CEO Har Grover said ”CannScience is working to develop its product pipeline which will include proprietary drug, device, and delivery technologies, On November 18, 2014, CannScience entered into a non-binding Letter of Intent with Generex to license Generex’s proprietary RapidMist™ drug delivery technologies to CannScience for the buccal delivery of cannabis derived products into the bloodstream.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $15 million market valuation GNBT is cheaper now than it has ever been and used to trade at a valuation close to $100 million at its highs in 2012. The Company does have $2.2 million in the treasury and carries $1.9 million in patents on the books however they are carrying significant debt with $7.4 million in accounts payable.
GNBT has been losing ground for years and the current reversal off the $0.0105 represents a significant shift for the stock. Whether GNBT can maintain this turnaround remains to be seen but the volume and steady accumulation in recent days are very positive indicators indeed. At just over a penny GNBT deserves to be on speculators radars.
Disclosure: we hold no position in GNBT either long or short and we have not been compensated for this article.
www.microcapdaily.com/...nology-corporation-otcmktsgnbt/18310/
www.newswire.ca/en/story/1488319/...reast-cancer-vaccine-trial
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Generex Biotechnology Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
7 | 514 | Generex Biotech Corp | schibi | Bezugs_Recht | 25.04.21 00:09 | |
| Generex! | Rajiva35 | 21.02.06 22:33 | ||||
| generex 922012...hat einer eine meinung? | charttechnik | 07.01.04 17:20 |